Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial

X
Trial Profile

Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Ixazomib (Primary) ; Dexamethasone; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms HOVON 143 MM
  • Most Recent Events

    • 20 Sep 2024 This trial has been completed in Belgium (Global end date: 2024-05-02) according to European Clinical Trials Database record.
    • 12 Dec 2023 Results analyzing cell subsets related to frailty status, their predictive value for treatment outcome, and their dynamics during treatment, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results assessing dynamics of frailty scores and impact on clinical outcome of non-transplant eligible patients with NDMM (NTE-NDMM) included in this study presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top